



SEBI REGISTRATION NUMBER: INH100006427  
BSE ENLISTMENT NUMBER: 5308

XX XX XXXX

SAGILITY LIMITED



RECOMMENDATION

BUY

FACE VALUE

₹10

MARKET PRICE

₹XXX

BSE CODE

544282

AS OF XX XX XXXX

TARGET PRICE

₹XXX

NSE CODE

SAGILITY



## ABOUT THE COMPANY

Sagility Limited is a pure-play healthcare-focused business process management company headquartered in Bengaluru, India. Formerly the captive BPM operations of Hinduja Global Solutions, the Company was carved out to serve leading U.S. healthcare payers and providers. It is listed on Indian stock exchanges and brings deep domain expertise in U.S. healthcare administration and operations.

The Company delivers a comprehensive suite of services spanning claims processing, clinical management, revenue cycle management, member and provider engagement, pharmacy benefit management support, and healthcare analytics. Sagility serves a diversified portfolio of health insurance payers, hospital systems, and physician groups, operating across multiple delivery centres in India and internationally.

Sagility is positioned as a specialist in the large and growing U.S. healthcare outsourcing market, leveraging technology, automation, and domain-trained talent to improve operational outcomes for its clients. The Company focuses on expanding wallet share with existing customers, winning new clients, and deepening capabilities in digital and AI-enabled healthcare administration solutions.



## Performance Highlights

### Q3 FY26 summary



- ▶ **19.9% Y-o-Y organic growth in Q3 FY26**, driven by continued expansion within existing clients, and increasing contribution from new clients acquired in FY26
- ▶ **\$30.5 M (potential steady state ACV)** of new business & expansion won in Q3 FY26
  - ▶ Expansion and new SOWs from 22 existing clients in Q3 FY26
  - ▶ **3 new clients** onboarded in Q3 (total 12 until Q3 FY26)
- ▶ Strong performance in Broadpath coming from AEP
- ▶ CSAT in 2025 surpassed the industry median, reflecting strong operational excellence, deep domain expertise, and our strategic & advisory engagement with clients.

### 9M FY26 summary



- ▶ **Innovator in RCM Business Process Transformation Avasant's RadarView™ 2025**
- ▶ Sagility is recognized among **India's Best Workplaces™ in Pharmaceuticals, Healthcare, and Biotech 2025**
- ▶ Earned the **Ecovadis Committed Badge** as a recognition to our strong performance in Sustainability
- ▶ Recognized at **HIMAP (Healthcare Information Management Association of the Philippines) 2025**





## KPIs

	Q3 FY26	Q2 FY26	Q3 FY25	YoY%	9M FY26	9M FY25	YoY%
<b>Revenue from Operation (in INR Million)</b>	<b>19,712</b>	<b>16,585</b>	<b>14,531</b>	<b>35.7%</b>	<b>51,686</b>	<b>40,014</b>	<b>29.2%</b>
Revenue by Vertical Split							
By Payer %	90.4%	88.5%	89.3%		89.2%	89.2%	
By Provider %	9.6%	11.5%	10.7%		10.8%	10.8%	
Growth in revenue from operation (%)	35.7%	25.2%	15.3%		29.2%	15.3%	
<b>Adjusted EBITDA (in INR Million)</b>	<b>5,125</b>	<b>4,352</b>	<b>4,127</b>	<b>24.2%</b>	<b>13,164</b>	<b>10,508</b>	<b>25.3%</b>
Adjusted EBITDA %	26.0%	26.2%	28.4%		25.5%	26.3%	
<b>Adjusted PAT (in INR Million)</b>	<b>3,229</b>	<b>3,010</b>	<b>2,626</b>	<b>23.0%</b>	<b>8,236</b>	<b>5,709</b>	<b>44.3%</b>
Adjusted PAT %	16.4%	18.1%	18.1%		15.9%	14.3%	
<b>Total Number of Employees</b>	<b>48,522</b>	<b>44,185</b>	<b>39,595</b>	<b>22.5%</b>	<b>48,522</b>	<b>39,595</b>	<b>22.5%</b>
Voluntary attrition rate* (%)	22.8%	26.3%	21.8%		24.7%	24.8%	

Note:

Adjusted EBITDA represents EBITDA adjusted for earnouts payable under acquisition agreements (DCI, BirchAI & BroadPath), share-based payment awards and exclude other income (including forex gain/loss).

Adjusted PAT includes adjustments to the EBITDA and adj. for amortisation of intangible assets that got created due to carveout of healthcare business from HGS & exceptional items (represents adjustment for labour codes)

Voluntary attrition (considering employees who were employees for more than 90 days) on an annualized basis

## Annual KPIs

	9M FY26	FY25	FY24	FY23
<b>Numbers of Client group</b>				
Active	81	75	44	35
Number of new client addition (Gross)	12	38	13	7
<b>Delivery Sites</b>				
Number of delivery sites	35	33	30	27
New site addition (Gross)	4	10	4	2
	TTM Dec 25	FY25	FY24	FY23
<b>Client groups contribution to revenues**</b>				
Top 3 Client %	60.1%	66.2%	68.3%	72.4%
Top 5 Client %	71.1%	77.9%	79.2%	80.6%
Top 10 Client %	84.6%	90.5%	91.4%	90.7%
<b>Number of Million-dollar client groups</b>				
Number of clients contributing more than US\$20 million	8	7	5	4
Number of clients contributing to US\$5 - US\$20 million	7	6	7	7
Number of clients contributing to US\$1 - US\$5 million	22	12	12	12
Number of clients contributing less than US\$1 million	44	50	20	12

- Client groups comprise client entities together with their affiliates.
- \*\*Client group represent top client based on last twelve months revenue for the respective period

## Recent Market Updates

### ACA subsidy expiration

- ▶ OEP 2026 provisional results indicate a decline in ACA selections by 3.4% largely due to expiration of Premium tax credits leading to increase in premiums.
- ▶ Health plans with heavy ACA exposure would be affected; some large insurers have not participated
- ▶ For service providers, outsourcing demand will shift toward post-enrollment support to protect membership and revenue; Sagility has very little exposure to ACA plans

### CMS proposed changes in 2027 in MA & Part D (2027)

- ▶ STARS focus shifting toward clinical safety and patient experience and away from low-value admin measures.
- ▶ This is likely to accelerate demand for clinical and care coordination, member experience, and behavioral health follow-up at scale.

### HEDIS Measurement Year 2026

- ▶ New HEDIS measures to increase focus on care coordination; push towards digital and FHIR-aligned reporting
- ▶ These changes are likely to increase demand for HEDIS abstraction and outreach support

### PBM Market evolution

- ▶ PBM market faces higher scrutiny on price transparency by both FTC and State regulatory affairs .
- ▶ Employers and Insurers demand higher accountability for clinical outcomes from PBMs.
- ▶ High-cost drugs such as GLP-1 demand stronger coverage policies and cost sharing by insured members

# Medicare AEP 2026 & ACA Marketplace OEP 2026

## Industry View

### Medicare



- ▶ National carriers reporting **Medicare AEP largely in line with expectations.**
- ▶ Payers shift **focus towards Margin Repair over Membership Growth** -better risk mix and higher-STAR cohorts, rather than higher enrollment.
- ▶ 2026 is expected to be a consolidation phase **with reduced participation in low-margin/high-utilization populations.**
- ▶ CMS overall data on AEP 2026 would be available Mid-Feb

Specific to Sagility's large payer relationships, AEP outcomes were broadly ahead of expectations

### ACA



- ▶ To date, there was **29% decline in new consumers and 3.4% decline in total enrollment** in 2026 vs 2025
- ▶ Expiration of ACA premium tax credits resulting in higher net premiums is leading to the churn

As mentioned earlier, Sagility has very low exposure to the ACA segment

## Implications



1. Higher administrative throughput (engagement service volumes, PA, claims, clinical workflows)
2. Cost management pressure
3. Heightened emphasis on Stars recovery, clinical quality, and automation.



Industry-wide, plans continue to shift budgets toward:

1. Digital/AI-led operating models
2. Outsourcing to improve margins while retaining plan benefits.

# Sagility Thought Leadership: What's New & What's Next for 2026

## GTM with Sagility Synchrony

**Sagility Synchrony®**  
A Medicare Advantage Lifecycle Solution.

Medicare Advantage plans are being asked to do more for increasingly complex, high-need member populations. This is coming at a time when costs are rising, regulatory scrutiny is intensifying, and error-prone enrollment and billing operations are putting MA Star Ratings at risk.

As 2027 bid and benefit decisions approach, many plans remain constrained by fragmented point solutions that were never designed to scale, integrate, or perform in today's healthcare ecosystem.

Sagility Synchrony® eliminates siloed operations by unifying plan filing, launch, sales, broker management, enrollment, billing, and reconciliation on an integrated, compliant workflow — accelerating time-to-market, improving data integrity, reducing audit risk, and minimizing friction in the member experience.

- Factor launches with lower risk
- Unified governance and accountability
- Elastic financial model that scales with membership
- Proven technology partners
- Compliance first design

**From Silos to a Single System.**

Plan Design	Enrollment
Automated plan configuration that streamlines plan design, CMS filings, and compliant documentation — using a centralized, reusable product database to speed approvals and ensure AEP readiness.	Licensed sales teams for direct-to-consumer and broker-led member acquisition; reducing broker fees through On-Booked scripts, guided plan comparison, and a broker-friendly portal.
Powered by  Simply Healthcare	Powered by  Sagility

Powered by convey

## Dynamic Content

### Sagility Consulting



### People and Data: Key to Member Experience Transformation



## White Paper & Case Studies

### Whitepaper

**Activating Outsourced Healthcare Operations**

A step-by-step playbook for speed, scale, and stability

### Case Studies

<b>GenAI Nurse Assist to Achieve Efficiencies, Faster Care</b>	<b>Reducing cost by 30% with Optimized Provider Data</b>
<b>Scaling Healthcare Operations with Geographical Flexibility &amp; Process Maturity</b>	<b>Unlocking Member Value with AI-Empowered Experiences</b>

**GenAI Client Use cases:** 32 client use cases deployed across 10 clients

# Financial Highlights

## Q3 FY26



REVENUE

₹ 19,712 million

**Y-o-Y growth**  
35.7%  
*29.1 % at Constant Currency*

**Organic Y-o-Y growth**  
19.9%  
*13.9 % at Constant Currency*



ADJUSTED EBITDA

₹ 5,125 million

**Margin %**  
26.0%

**Y-o-Y growth %**  
24.2%



ADJUSTED PAT

₹ 3,229 million

**Margin %**  
16.4%

**Y-o-Y growth %**  
23.0%



OCF

₹ 1,117 million

**Conversion %**  
21.7%

**DSO**  
86 days

## 9M FY26



REVENUE

₹ 51,686 million

**Y-o-Y growth**  
29.2%  
*24.2 % at Constant Currency*

**Organic Y-o-Y growth**  
18.0%  
*13.5 % at Constant Currency*



ADJUSTED EBITDA

₹ 13,164 million

**Margin %**  
25.5%

**Y-o-Y growth %**  
25.3%



ADJUSTED PAT

₹ 8,236 million

**Margin %**  
15.9%

**Y-o-Y growth %**  
44.3%



OCF

₹ 6,708 million

**Conversion %**  
49.7%

**DSO**  
86 days



Higher Revenues in Q3 leading to increase in DSO to 86 days ( AR 51 Days, Unbilled 35 days) & Drop in cash conversion

## Quarterly Seasonality




Higher growth in Q3 driven by strong AEP for Broadpath & Sagility Organic business

## Long Term Financial performance snapshot






Consistent Revenue & EBITDA growth. Reduction in interest and amortization expense driving higher PAT growth



\*Adjusted EBITDA represents EBITDA adjusted for earnouts payable under the acquisition agreements (DCI, BirchAI, & BroadPath), share-based payment awards and exclude other income (including forex gain/loss).

## Other Financial Indicators



**Steady Increase in Adjusted EPS. Adjusted ROCE consistent at 50%. Lower cash conversion in YTD Dec'25 due to higher DSO, Non cash gains & taxes**

Adjusted EPS is Adjusted PAT divided by weighted average number of equity shares  
 Adjusted ROCE is Adjusted PAT plus Interest cost divided by capital employed (Assets excluding goodwill and intangibles assets less current liabilities)  
 Net Debt is Borrowing plus lease liabilities less Cash and Cash equivalent including investment in Mutual Fund and Deposits . Borrowing doesn't include accrued interest

## Q3 FY26 Consolidated Profit and Loss

Particulars						Amt in INR M		
	Q3 FY26	Q2 FY26	Q3 FY25	YoY%	QoQ%	9M FY26	9M FY25	YoY%
<b>Revenue from Operation</b>	<b>19,712</b>	<b>16,585</b>	<b>14,531</b>	<b>35.7%</b>	<b>18.9%</b>	<b>51,686</b>	<b>40,014</b>	<b>29.2%</b>
Employee benefits expense	12,211	10,070	8,415			31,926	23,854	
Other expenses <sup>^</sup>	2,376	2,163	1,988			6,596	5,652	
<b>Adjusted EBITDA**</b>	<b>5,125</b>	<b>4,352</b>	<b>4,127</b>	<b>24.2%</b>	<b>17.8%</b>	<b>13,164</b>	<b>10,508</b>	<b>25.3%</b>
Adjusted EBITDA %	26.0%	26.2%	28.4%			25.5%	26.3%	
<b>Adjustments:</b>								
M&A Earnouts	42	127	120			324	364	
SAR (stock appreciation right) - NonCash	-61	73	85			83	1,030	
Other Income (excl. Forex gain) <sup>^^</sup>	84	65	99			199	287	
Forex Gain / (Loss)	-33	516	341			533	309	
<b>Reported EBITDA</b>	<b>5,195</b>	<b>4,733</b>	<b>4,362</b>	<b>19.1%</b>	<b>9.8%</b>	<b>13,488</b>	<b>9,710</b>	<b>38.9%</b>
Finance costs	247	250	302			771	973	
Depreciation and amortisation expenses	1,235	1,215	1,162			3,632	3,525	
<b>Profit before Exceptional Items</b>	<b>3,713</b>	<b>3,268</b>	<b>2,898</b>	<b>28.1%</b>	<b>13.6%</b>	<b>9,085</b>	<b>5,212</b>	<b>74.3%</b>
<b>Statutory impact of new labour code in India</b>	<b>328</b>					<b>328</b>		
<b>Profit Before Tax</b>	<b>3,385</b>	<b>3,268</b>	<b>2,898</b>	<b>16.8%</b>	<b>3.6%</b>	<b>8,757</b>	<b>5,212</b>	<b>68.0%</b>
Tax Expenses	709	760	729			2,087	1,647	
<b>Reported Profit After Tax</b>	<b>2,677</b>	<b>2,508</b>	<b>2,169</b>	<b>23.4%</b>	<b>6.7%</b>	<b>6,670</b>	<b>3,565</b>	<b>87.1%</b>
<b>EPS</b>	<b>0.57</b>	<b>0.53</b>	<b>0.46</b>	<b>23.9%</b>	<b>6.9%</b>	<b>1.42</b>	<b>0.78</b>	<b>82.7%</b>
<b>Adjusted PAT</b>	<b>3,229</b>	<b>3,010</b>	<b>2,626</b>	<b>23.0%</b>	<b>7.3%</b>	<b>8,236</b>	<b>5,709</b>	<b>44.3%</b>
Adjusted PAT %	16.4%	18.1%	18.1%			15.9%	14.3%	
<b>Adjusted EPS (Rs)</b>	<b>0.69</b>	<b>0.64</b>	<b>0.56</b>	<b>23.0%</b>	<b>7.3%</b>	<b>1.76</b>	<b>1.24</b>	<b>41.7%</b>

### New Labour Code in India effective 21Nov 2025:

- ▶ Prescribes uniform definition of wages based on which employee benefits like gratuity, leave encashment & statutory bonus are computed.
- ▶ Past service costs of INR 294.7M towards Gratuity and INR 33.5M towards Compensated absence reported as exceptional items in Q3.
- ▶ Ongoing impact on overall Margins is likely to be 0.2% of Revenues.

\*Employee benefits expense excludes M&A earnout and SAR (shown separately under adjustments).


<sup>^</sup> Other expenses exclude forex loss. <sup>^^</sup> Other income excludes forex gain. Forex Gain and Forex Loss clubbed together and shown separately.

\*\* Adjusted EBITDA represents EBITDA adjusted for earnouts payable under the acquisition agreements (DCI, BirchAI & BroadPath), share-based payment awards and exclude other income (including forex gain/loss).

## Adjustments on EBITDA and PAT


**Adj EBITDA Bridge: Q3 FY26**

Amt in INR M




**Adj EBITDA Bridge: 9M FY26**

Amt in INR M



**Adj PAT Bridge: Q3 FY26**



**Adj PAT Bridge: 9M FY26**



Adj A - Earnouts under acquisition agreements and for PAT it is adjusted for tax

Adj B - Share based payment awards (non-cash expenses for the company and not tax deductible)

Adj C - Amortization of intangible assets (net of tax) that got created due to carveout of healthcare business from HGS

Adj D- Exceptional items for Q3 FY26 represents adjustment for labour codes (net of deferred tax) on account of increase in gratuity liability arising out of past service cost and increase in leave liability

## Go Forward Positions

*Amt in INR M*

Particulars	FY25	FY26	FY27	FY28	FY29	FY30
Closing Debt position	8,020	5,670				
Debt Repayment	2,490	2,350	5,670			
Interest Payment	751	535	285			
Share based Payment awards	1,134	117	117	62	30	
Earnouts Cost - DCI / Birch/ BroadPath	571	420	6			
Intangibles Amortisation (A)	1,400	1,451	1,487	1,487	1,487	1,487
Intangibles Amortisation (B)	188	391	388	374	297	252

**Debt to be fully repaid by FY27.**

- *Intangibles Amortisation (A) - Amortization of intangible assets that got created due to carveout of healthcare business from HGS*
- *Intangibles Amortisation (B) - Amortisation for intangible assets acquired in relation to acquisitions (DCI, Birch and BroadPath) – Ends by FY33*



# QUARTERLY RESULTS

AS OF DEC '25

Consolidated Quarterly Results	Dec '25	Sep '25	Jun '25	Mar '25	Dec '24
Net Sales/Income from operations	1,971.15	1,658.50	1,538.94	1,568.48	1,453.07
Other Operating Income	--	--	--	--	--
Total Income From Operations	1,971.15	1,658.50	1,538.94	1,568.48	1,453.07
<b>Expenditure</b>	--	--	--	--	--
Consumption of Raw Materials	--	--	--	--	--
Purchase of Traded Goods	--	--	--	--	--
Increase/Decrease in Stocks	--	--	--	--	--
Power & Fuel	--	--	--	--	--
Employees Cost	1,219.16	1,027.02	987.21	974.10	862.00
Depreciation	123.52	121.51	118.19	114.34	116.17
Excise Duty	--	--	--	--	--
Admin. And Selling Expenses	--	--	--	--	--
R & D Expenses	--	--	--	--	--
Provisions And Contingencies	--	--	--	--	--
Exp. Capitalised	--	--	--	--	--
Other Expenses	240.89	216.34	205.64	221.35	198.84
P/L Before Other Inc., Int., Excpt. Items & Tax	387.59	293.63	227.90	258.70	276.05
Other Income	8.42	58.17	9.89	10.12	43.95
P/L Before Int., Excpt. Items & Tax	396.01	351.80	237.80	268.82	320.01
Interest	24.66	24.99	27.41	29.83	30.19
P/L Before Exceptional Items & Tax	371.34	326.81	210.39	238.99	289.81
Exceptional Items	-32.82	--	--	--	--
P/L Before Tax	338.52	326.81	210.39	238.99	289.81
Tax	70.87	75.98	61.83	56.41	72.90
P/L After Tax from Ordinary Activities	267.66	250.83	148.56	182.57	216.91
Prior Year Adjustments	--	--	--	--	--
Extra Ordinary Items	--	--	--	--	--
Net Profit/(Loss) For the Period	267.66	250.83	148.56	182.57	216.91
Minority Interest	--	--	--	--	--
Share Of P/L Of Associates	--	--	--	--	--
Net P/L After M.I & Associates	267.66	250.83	148.56	182.57	216.91
Equity Share Capital	4,679.27	4,679.27	4,679.27	4,679.27	4,679.27
Reserves Excluding Revaluation Reserves	--	--	--	--	--
Equity Dividend Rate (%)	--	--	--	--	--
<b>EPS Before Extra Ordinary</b>	--	--	--	--	--
Basic EPS	0.57	0.53	0.32	0.39	0.46
Diluted EPS	0.57	0.53	0.32	0.39	0.46
<b>EPS After Extra Ordinary</b>	--	--	--	--	--
Basic EPS	0.57	0.53	0.32	0.39	0.46
Diluted EPS	0.57	0.53	0.32	0.39	0.46



# ANNUAL RESULTS

AS OF MAR '25

Consolidated Annual Results	Mar '25	Mar '24	Mar '23	Mar '22
Net Sales/Income from operations	5,569.92	4,753.56	4,218.41	923.41
Other Operating Income	--	--	--	--
Total Income From Operations	5,569.92	4,753.56	4,218.41	923.41
<b>Expenditure</b>	--	--	--	--
Consumption of Raw Materials	--	--	--	--
Purchase of Traded Goods	--	--	--	--
Increase/Decrease in Stocks	--	--	--	--
Power & Fuel	--	--	--	--
Employees Cost	3,498.90	2,937.64	2,494.20	505.71
Depreciation	466.86	689.21	644.34	147.21
Excise Duty	--	--	--	--
Admin. And Selling Expenses	--	--	--	--
R & D Expenses	--	--	--	--
Provisions And Contingencies	--	--	--	--
Exp. Capitalised	--	--	--	--
Other Expenses	773.14	727.82	697.00	228.11
P/L Before Other Inc., Int., Excpt. Items & Tax	831.03	398.88	382.87	42.38
Other Income	56.31	27.95	17.65	20.99
P/L Before Int., Excpt. Items & Tax	887.33	426.83	400.53	63.36
Interest	127.10	185.15	214.85	65.22
P/L Before Exceptional Items & Tax	760.23	241.68	185.68	-1.85
Exceptional Items	--	--	--	--
P/L Before Tax	760.23	241.68	185.68	-1.85
Tax	221.11	13.42	42.11	2.82
P/L After Tax from Ordinary Activities	539.12	228.27	143.57	-4.67
Prior Year Adjustments	--	--	--	--
Extra Ordinary Items	--	--	--	--
Net Profit/(Loss) For the Period	539.12	228.27	143.57	-4.67
Minority Interest	--	--	--	--
Share Of P/L Of Associates	--	--	--	--
Net P/L After M.I & Associates	539.12	228.27	143.57	-4.67
Equity Share Capital	4,679.27	4,285.28	1,918.67	1,918.67
Reserves Excluding Revaluation Reserves	3,656.78	2,157.85	-2,409.91	-4,589.97
Equity Dividend Rate (%)	--	--	--	--
<b>EPS Before Extra Ordinary</b>	--	--	--	--
Basic EPS	1.17	0.53	0.33	-0.05
Diluted EPS	1.17	0.53	0.33	-0.05
<b>EPS After Extra Ordinary</b>	--	--	--	--
Basic EPS	1.17	0.53	0.33	-0.05
Diluted EPS	1.17	0.53	0.33	-0.05



# KEY FINANCIAL RATIOS


AS OF MAR '25

Consolidated Key Financial Ratios	Mar '25	Mar '24	Mar '23	Mar '22
<b>Investment Valuation Ratios</b>	--	--	--	--
Face Value	10.00	10.00	10.00	10.00
Dividend Per Share	--	--	--	--
Operating Profit Per Share (Rs)	2.77	2.54	5.35	0.99
Net Operating Profit Per Share (Rs)	11.90	11.09	21.96	4.81
Free Reserves Per Share (Rs)	--	--	--	--
Bonus in Equity Capital	--	--	--	--
<b>Profitability Ratios</b>	--	--	--	--
Operating Profit Margin(%)	23.30	22.89	24.35	20.53
Profit Before Interest And Tax Margin(%)	14.77	8.34	9.03	4.48
Gross Profit Margin(%)	14.91	8.39	9.07	4.58
Cash Profit Margin(%)	17.88	19.18	18.60	15.09
Adjusted Cash Margin(%)	17.88	19.18	18.60	15.09
Net Profit Margin(%)	9.67	4.80	3.40	-0.50
Adjusted Net Profit Margin(%)	9.58	4.77	3.38	-0.49
Return On Capital Employed(%)	9.69	5.09	4.68	0.76
Return On Net Worth(%)	6.46	3.54	-29.22	0.17
Adjusted Return on Net Worth(%)	6.46	3.54	--	--
Return on Assets Excluding Revaluations	17.81	15.03	-2.56	-13.91
Return on Assets Including Revaluations	17.81	15.03	-2.56	-13.91
Return on Long Term Funds(%)	9.96	5.26	21.85	4.18
<b>Liquidity And Solvency Ratios</b>	--	--	--	--
Current Ratio	0.86	0.70	0.95	0.76
Quick Ratio	1.01	0.81	0.94	0.80
Debt Equity Ratio	0.10	0.30	--	--
Long Term Debt Equity Ratio	0.07	0.26	--	--
<b>Debt Coverage Ratios</b>	--	--	--	--
Interest Cover	6.98	2.31	1.86	0.97
Total Debt to Owners Fund	0.10	0.30	--	--
Financial Charges Coverage Ratio	10.65	6.03	4.86	3.23
Financial Charges Coverage Ratio Post Tax	8.91	5.96	4.67	3.19
<b>Management Efficiency Ratios</b>	--	--	--	--
Inventory Turnover Ratio	--	--	--	--
Debtors Turnover Ratio	4.55	4.23	4.23	--
Investments Turnover Ratio	0.61	0.57	2.27	0.59
Fixed Assets Turnover Ratio	3.72	3.41	3.94	1.07
Total Assets Turnover Ratio	5.17	7.21	5.46	2.00
Asset Turnover Ratio	0.64	0.56	0.50	--
Average Raw Material Holding	--	--	--	--
Average Finished Goods Held	--	--	--	--
Number of Days In Working Capital	9.20	-22.34	6.75	-27.41
<b>Profit &amp; Loss Account Ratios</b>	--	--	--	--
Material Cost Composition	--	--	--	--
Imported Composition of Raw Materials Consumed	--	--	--	--
Selling Distribution Cost Composition	--	--	--	--
Expenses as Composition of Total Sales	--	--	--	--
<b>Cash Flow Indicator Ratios</b>	--	--	--	--
Dividend Payout Ratio Net Profit	--	--	--	--
Dividend Payout Ratio Cash Profit	--	--	--	--
Earning Retention Ratio	100.00	100.00	100.00	--
Cash Earning Retention Ratio	100.00	100.00	100.00	100.00
AdjustedCash Flow Times	0.81	2.11	2.98	29.74



## SHAREHOLDING PATTERN

AS OF DEC '25





## SUMMARY

- On quarterly basis, the Company delivered steady performance in Q3 of FY'26, with Net Sales up by 35.65% i.e. Rs. 1,971.15 crs in Dec '25 as compared to Rs. 1,453.07 crs in Dec '24. Moreover, the Net Profits too showed a rise of 23.40% i.e. Rs. 267.66 crs in Dec '25 as compared to Rs. 216.91 crs in Dec '24.
- As per sound financials and healthy fundamentals, the Company is available at a good price of Rs. XXX with its 52 week low at Rs. 37.25 and its 52 week high at Rs. 57.89.
- Since the Promoters are holding a majority stake around 50.95%, it is fair to assume that the Management is committed to growth of the Company.
- The Shareholding Pattern shows that the FIIs and the Other DIIs collectively stood with 18.25% stake. Whilst, the Mutual Fund Houses own 13.36% holdings in the Company.
- It is reassuring to see that Sagility Limited is held by AXIS MF, BANDHAN MF, BARODA BNP PARIBAS MF, CANARA ROB MF, FRANKLIN MF, HSBC MF, ICICI PRU MF, KOTAK MF, MAHINDRA MANULIFE MF, MIRAE ASSET MF, MOTILAL OSWAL MF, PGIM INDIA MF & MORE.
- On consolidated basis, Sagility Limited registered Return on Equity (ROE) and Return on Capital Employed (ROCE) around 6.46% & 9.69% respectively as on Mar '25.



# DISCLOSURES

Copyright © Parveen Kumar Sharma, Proprietor of 10Paisa.com. Any act of copying or distributing this report in part or in full, for any purpose, without my permission, is strictly prohibited and would be a copyright infringement.

## Disclosures as required under SEBI (Research Analyst) Regulations, 2014

### Introduction:

I, Parveen Sharma, am the proprietor of 10Paisa.com and a SEBI-registered Research Analyst (Registration No.: INH100006427). I provide research and advisory services through my website, 10Paisa.com, which primarily focuses on the analysis of small-cap stocks in India. I have been offering stock recommendations through the platform since November 2004. Prior to obtaining SEBI registration, I developed extensive educational material comprising over 500 slides covering fundamental analysis, technical analysis, and value investing, which were used for investor education purposes.

### Business Activity:

I provide research services on equity stocks listed on Indian stock exchanges. The research is based on fundamental analysis. I do thorough research and analysis on fundamentals of companies. As such, I undertake extensive scrutiny of major Company statistics like Balance Sheet, Profit & Loss Account, Key Financial Ratios (ROE, ROCE and Debt to Equity etc.), Quarterly, Half-yearly & Annual Results, Cash Flows, Annual Reports and Shareholding Pattern etc. Each Company's Business Model, Future Projections, Competitive Advantages & other Moats are thoroughly checked before recommending their Stock.

I offer services to the subscribers through the following:

1. 10Paisa.com
2. Midcaps.in
3. MidtoMega.com
4. SmallStocks.in
5. Largecaps.in

### Disciplinary History

There is no disciplinary action which is / was running / initiated against me or my firm and there are no out-standing litigations against me.

### General Terms and Conditions for SmallStocks.in:

1. Every week, 2 stock recommendations will be provided to the subscribers.
2. The subscribers have to login in their account through login credentials provided to them at the time of subscription.
3. The reports should not be considered as an investment advice or personal recommendation.
4. I and my team members will not be liable for any loss or liability incurred to the user due to investments made or decisions taken based on the information provided in the reports.
5. All of the views and opinions expressed in research reports, issued after due diligence and careful study, reflect my unbiased analysis of the Company or Companies as on the date of the report.
6. Still, it is advised that the users should rely on their own research and analysis as well as consult their own investment advisors to determine the suitability of recommendation.
7. Past performance of a Company is no guarantee for future performance or future results.
8. My service is not suitable to investors who are looking for intraday calls i.e. day trading or futures & options in stocks and indexes on basis of technical analysis.

[Click here](#) to view the terms and conditions of the website.



**List of Associates / Relatives:**

1. My spouse, Mrs. Priya Sharma
2. My daughter, Ms. Priyanka Sharma
3. My son, Master Priyanshu Sharma

Note: Subject Company is a company on which buy/sell recommendation or target price is given or changed in the research report.

**Disclosure with regards to ownership and material conflicts of interest:**

1. Neither I nor my associates / relatives have financial interest in the subject company.
2. Neither I nor my relatives / associates have actual/beneficial ownership of 1% or more in securities of the subject company, at the end of the month immediately preceding the date of publication of the document.
3. Neither I nor my relatives / associates have any other material conflict of interest at the time of publication of the document.

**Disclosure with regards to receipt of compensation:**

1. Neither I nor my associates / relatives have received any compensation from the subject company in the past 12 months.
2. Neither I nor my associates / relatives have managed or co-managed public offering of securities for the subject company in the past 12 months.
3. Neither I nor my associates / relatives have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months.
4. Neither I nor my associates / relatives have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.
5. Neither I nor my associates / relatives have received any compensation or other benefits from the subject company or third party in connection with the document.

**General Disclosures:**

1. I have not served as an officer, director or employee of the subject company.
2. I am not engaged in market making activity for the subject company.

**Definition of terms used:**

1. Buy Recommendation: The subscribers can buy the shares of the subject company at the current market price.
2. Sell Recommendation: The subscribers can sell the shares of the subject company when the market price of the subject company hits the target price.

**"Investments in Securities Market are subject to market risks. Read all the related documents carefully before investing".**

**"Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors".**

Mr. Parveen Kumar Sharma, Proprietor of 10Paisa.com  
SEBI Registered "Research Analyst" Reg. No. INH100006427

Contact: 7814321795

Email: info.smallstocks@gmail.com

Address: #582, Phase 2, Mohali (Pb.)

# OUR RESEARCH NETWORK

EXPLORE SPECIALISED RESEARCH PLATFORMS WITHIN OUR NETWORK



EMERGING SMALLCAP  
STOCK RESEARCH

[VIEW WEBSITE](#)



DYNAMIC MIDCAP  
STOCK RESEARCH

[VIEW WEBSITE](#)



CORE LARGE CAP  
STOCK RESEARCH

[VIEW WEBSITE](#)



STOCKS BELOW  
HUNDRED RUPEES

[VIEW WEBSITE](#)



LONG HORIZON  
STOCK RESEARCH

[VIEW WEBSITE](#)

33+ YEARS OF EXPERIENCE

780+ REPORTS GENERATED

42+ SECTORS ANALYSED

18,000+ RESEARCH HOURS